Biotechnology in Thoughts from the Centre

Reducing health inequalities and improving access to medicine through access and affordability programmes

By Elizabeth Hampson, Director Monitor Deloitte

LSHC blog banner image 5 Dec

Today, over a quarter of the world’s population has no access to essential medicines and, for more than two billion people worldwide, medicines may be unaffordable, unavailable, inaccessible or non-quality assured.1 2 With statistics this stark, and the increased awareness (due to the COVID-19 pandemic) of the impact of both global and national health inequalities on health outcomes, there is a need for much better awareness and more targeted action to improve access to medicine for all.

Continue reading

Posted on 10/12/2021 | 0 Comments

COP26 – Our hopes for a healthier, collaborative, interconnected future

By Giles Dean, Sustainability Manager, and James Gregson, Partner, UK Life Sciences and Healthcare leader

Cop-26

The research evidence is unequivocal, public, planetary and economic health are inextricably linked and no continent, country or community is immune from the impacts of climate change. The race to net zero is also a race to a healthier, cleaner and more resilient future. We hope that the undeniable link between improving the health outcomes of society and a successful net-zero transition will be central to COP26. This blog outlines a discussion between Giles Dean, Sustainability Manager at Deloitte UK,  and James Gregson, Partner and UK Life Sciences and Healthcare leader, on their hopes for COP26 and the implications for healthcare and, specifically the pharmaceutical (pharma) industry, across not just environmental, but also social and governance (ESG) indicators.1

Continue reading

Posted on 03/11/2021 | 0 Comments

These strategies could boost diversity in clinical trials

By Margaret Anderson, managing director, Deloitte Consulting LLP

6a01543429fb37970c0263e99490e4200b-800wi
Clinical trials take data from a small, but representative selection of subjects and generalise the findings to the wider population. However, as we have discussed in our previous blogs on the subject, Why improving inclusion and diversity in clinical trials should be a research priority and Diversity and inclusion in clinical trials – an imperative, especially in times of COVID-19, overcoming the lack of diversity in clinical trials is a medical and ethical imperative to achieve true representation of the patient population. This week’s blog, by Margaret Anderson, our Strategy & Analytics Diversity, Equity and Inclusion Leader in Deloitte Consulting, appeared first as a US Center for Health Solutions, Health Forward Blog and reflects on the stakeholder interviews our US colleagues conducted to understand how diversity could be improved in clinical trials.

Continue reading

Posted on 01/10/2021 | 0 Comments

Beyond COVID-19: Unlocking the power of mRNA vaccines and therapies

By Pratik Avhad, Senior Analyst, and Maria João Cruz, PhD, Assistant Research Manager, Centre for Health Solutions

Beyond COVID-19

Since the start of the COVID-19 pandemic, more than 218 million cases and over 4.5 million COVID-related deaths have been reported worldwide, numbers that continue to grow.1 As long as the SARS-CoV-2 virus is in circulation, it will have an opportunity to mutate into potentially more infectious strains and remain an ever-moving target. Vaccines are an essential tool in the arsenal to combat this pandemic.2 To date, six vaccines have been approved for emergency or full use by at least one WHO-recognised stringent regulatory authority. All have been proven to be safe and effective at preventing severe disease, hospitalisation and COVID-related death.3 Vaccine developers are using a variety of technologies and techniques from the tried and tested to completely novel approaches. The first vaccine to receive emergency approval was a first-in-class synthetic messenger RNA (mRNA) vaccine4, making RNA a household word. Even though mRNA technology itself is not new, its clinical reality is still nascent and this blog explores its concept and considers what future uses might emerge.

Continue reading

Posted on 03/09/2021 | 0 Comments

Reflections from a research analyst: Five reasons I’m glad I joined Deloitte

By Krissie Ferris, Research Analyst, Centre for Health Solutions

Reflections from research

This is my last week in the Deloitte Centre for Health Solutions, my home at Deloitte for almost two years. I'm not moving far though as I’m joining Deloitte’s Technology Digital Risk (TDR) Public Sector Health team, where I’ll be working with clients across the NHS and the wider healthcare industry to digitise ways of working and to help realise the huge opportunities for operational efficiencies and improved patient outcomes that can be enabled through technology. Having started my career in the NHS, I’m excited to start this new chapter and bring with me the knowledge and skills I’ve developed in my research role at the Centre. This blog reflects on my fabulous time at Deloitte so far and shares some of the reasons I’m looking forward to joining the health team.

Continue reading

Posted on 27/08/2021 | 0 Comments

Reputational reset: How digital capabilities can help biopharma companies (re)build consumer trust

By Jonathan Fox, Managing Director, Deloitte Consulting US, and Hanno Ronte, Partner, Monitor Deloitte UK

2021-05-07_18-08-54

Let’s talk about trust, specifically, consumer trust in biopharmaceutical (biopharma) manufacturers. Why do consumers trust or distrust biopharma companies? What do consumers think biopharma should do to increase trust? Can companies use digital capabilities to build, or in some cases rebuild, consumer trust? Why is trust important? These were some of the questions we discussed at a digital leader’ roundtable event at LSX’s World Congress USA event which Deloitte was a sponsor. This week’s blog provides our personal take on the key takeaways to emerge from that discussion.

Continue reading

Posted on 30/07/2021 | 0 Comments

Event highlights: Pharma R&D productivity and learnings from the pandemic

By Dr Maria João Cruz, PhD, Assistant Manager, Centre for Health Solutions

Deloitte-event-highlights

Following the launch of our eleventh annual report ‘Seeds of change: Measuring the return from pharmaceutical innovation 2020’, our UK and US Life Sciences R&D lead partners, Colin Terry and Neil Lesser, hosted a webinar with R&D executives from Pfizer and Novartis to discuss R&D productivity. The discussion also covered the impact of the COVID-19 pandemic on productivity. This week’s blog covers the main takeaways from this insightful discussion that resonated the most with me.

Continue reading

Posted on 02/07/2021 | 0 Comments

Integrating climate commitments into Pharma’s DNA: Good for business, the environment and public health

By Emily May, Research Analyst, Centre for Health Solutions

Integrating climate banner image-final

Last week, our Life Sciences & Healthcare UK leader James Gregson moderated a Reuters’ webinar, Pharma’s climate goals: The roadmap to delivery, with leaders from AstraZeneca, Roche and Health Care Without Harm. The discussion focused on the current pharma sustainability landscape and how to collaborate, accelerate and deliver climate commitments and embed them into pharma organisations’ DNA.1 Healthcare’s carbon footprint is estimated to have increased by 40 per cent since 1990 providing the pharma industry with an opportunity and responsibility to make a real difference. While there are promising signs across the sector of an increased willingness and commitment to counteract climate change, including adopting a more stringent timetable by which to meet carbon net-zero goals, the panel discussion and the focus of this blog is whether the pace of change is advancing fast enough and what more do companies need to do?

Continue reading

Posted on 25/06/2021 | 0 Comments

What is the outlook for the global life sciences industry in 2021?

By Dr Maria João Cruz, PhD, Assistant Manager, and Emily May, Research Analyst, Centre for Health Solutions

GLS

Each year, Deloitte produces a report exploring the outlook for the life sciences sector. This year’s report, 2021 global life sciences outlook: Possibility is now reality, sustaining forward momentum, explores the many ways COVID-19 has accelerated change for the life sciences and MedTech sectors and what can be reimagined and made better. As a result of the pandemic, novel technologies that were expected to advance over a decade were adopted in a few months, weeks, and sometimes, even days and many organisations embraced this unprecedented pace of change. This week’s blog covers highlights from the report, with a specific focus on how sustaining and institutionalising new ways of working, collaborating and operating digitally, can help companies succeed and contribute towards a more compassionate and equitable world.

Continue reading

Posted on 11/06/2021 | 0 Comments

Measuring the return from pharmaceutical innovation– have the seeds of change been sown?

By Dr Maria João Cruz, PhD, Assistant Manager, UK Centre for Health Solutions, and Sonal Shah, Senior Manager, US Center for Health Solutions

Untitled-3

This week we launched Seeds of change: Measuring the return from pharmaceutical innovation 2020, the 11th report in our series on biopharmaceutical (biopharma) R&D. Since 2010, we have provided insights into the state of biopharma R&D by tracking the returns that leading global biopharma companies might expect to achieve from their late-stage pipelines. While the past few years has seen an increase in breakthrough advances in science and technology, the growing complexity of development and longer cycle times have reduced the average internal rate of return (IRR) for the cohort of companies covered by our research and placed mounting pressures on the industry. In addition, over the past 16 months, the search for treatments and vaccines against the COVID-19 virus have galvanised innovation at an unprecedented pace and scale. At the same time, many non-COVID-19 clinical trials have been delayed or even halted. This week’s blog explores our 2020 report findings and how companies can realise a productive future for drug development.

Continue reading

Posted on 28/05/2021 | 0 Comments